tenalisib

Ligand id: 9907

Name: tenalisib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 96.7
Molecular weight 415.14
XLogP 5.45
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
3-(3-fluorophenyl)-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-4H-chromen-4-one
International Nonproprietary Names
INN number INN
10249 tenalisib
Synonyms
RP-6530 | RP6530
Comments
Tenalisib (RP6530) is an orally active dual PI3K δ/γ inhibitor that is being developed by Rhizen Pharmaceuticals for the potential oral treatment of cancer and inflammation. The chemical structure and its use are claimed in patent US9790224 where it is called Compound A1 [2].
Database Links
CAS Registry No. 1639417-53-0 (source: WHO INN record)
GtoPdb PubChem SID 363894201
PubChem CID 86291103
Search Google for chemical match using the InChIKey HDXDQPRPFRKGKZ-INIZCTEOSA-N
Search Google for chemicals with the same backbone HDXDQPRPFRKGKZ
Search PubMed clinical trials tenalisib
Search PubMed titles tenalisib
Search PubMed titles/abstracts tenalisib
Search UniChem for chemical match using the InChIKey HDXDQPRPFRKGKZ-INIZCTEOSA-N
Search UniChem for chemicals with the same backbone HDXDQPRPFRKGKZ